Court Square Capital Partners has acquired a majority stake in clinical research organisation Celerion Holdings from MTS Health Investors.

Both Court Square and MTS Health are private equity firms.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

All the entities involved in the acquisition are based in the US.

Quotient Sciences has acquired contract development and manufacturing organisation Pharmaterials.

This acquisition enables the drug development services organisation to expand its services in the UK.

Both Quotient Sciences and Pharmaterials are based in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“PhoenixBio plans to acquire Canadian in-vivo research services provider KMT Hepatech for C$5.5m ($4.33m).”

Jinzi Ham plans to acquire a 37.14% stake in NovaBay Pharmaceuticals for $27.06m.

Jinzi Ham is a Chinese food production company, whereas NovaBay Pharmaceuticals is a US-based biopharmaceutical company.

PhoenixBio plans to acquire Canadian in-vivo research services provider KMT Hepatech for C$5.5m ($4.33m).

KMT Hepatech will become a subsidiary of the Japanese life-science company upon completion of the acquisition.

Arlington Capital Partners has acquired a majority stake in contract, development, and manufacturing organisation Grand River Aseptic Manufacturing (GRAM).

Both the companies involved are based in the US.